Pt
|
MRSA prevalence of all inpatients
|
3.08%
|
1.20%
|
5.30%
|
[12]
|
Pr
|
MRSA prevalence of high-risk inpatients
|
11.94%
|
3.85%
|
20.6%
|
[12]
|
Pn.i.
|
MRSA prevalence of patients without indication for a targeted screening
|
0.03%
|
0.03%
|
0.03%
|
[13]
|
RTno iso
|
Rate of MRSA transmission not in isolation per day
|
0.029
|
0.0014
|
0.1400
|
[12]
|
RTiso
|
Rate of MRSA transmission in isolation per day
|
0.003
|
0.0008
|
0.0090
|
[12]
|
SenPCR
|
Sensitivity of PCR method
|
91.09%
|
62.50%
|
100%
|
[12]
|
Sencul
|
Sensitivity of culture method
|
88.73%
|
53.00%
|
100%
|
[12]
|
SPPCR
|
Specificity of PCR method
|
95.79%
|
83.70%
|
100%
|
[12]
|
SPcul
|
Specificity of culture method
|
93.23%
|
68.00%
|
100%
|
[12]
|
|
Average costs for pre-emptive isolation per day
|
62.77 €
|
9.45 €
|
145.11 €
|
[12]
|
|
Average costs per MRSA case per day
|
506.92 €
|
213.51 €
|
1,411.44 €
|
[12]
|
∅ LOSMRSA
|
Average length of stay of MRSA patients in days |
24.88 |
18 |
39 |
[12] |